Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 433 participants.

Also called NCT01787396

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 433 participants (enrolled count) (from the registry)
Sponsor
Registry
  • NCT NCT01787396
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
South Korea (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01787396. Randomized; quadruple masking; primary purpose treatment. Start 2013-04 (registry gives no type); primary completion 2015-03 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Trial to Evaluate the Efficacy and Safety of Initial Combination Therapy With Gemigliptin 50mg q.d and Metformin q.d
Condition
Type 2 Diabetes Mellitus
Intervention (Drug)
Gemigliptin 50mg
Intervention (Drug)
Placebo(Metformin)
Intervention (Drug)
Metformin
Intervention (Drug)
Placebo(Gemigliptin)
Lead sponsor
LG Life Sciences (class: industry)

Record details

Record id
cardio:ct-nct01787396
Content hash
54b9c36aef9016bc7f2ff1ba67ea08a82e4d7ac2f2da92529cfc9c4bd9e2a843